BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 16, 2013
 |  BC Week In Review  |  Company News  |  Deals

Evotec, J&J deal

Evotec said it will not receive a $6 million preclinical milestone from partner Johnson & Johnson under a 2012 deal for depressive disorders. As a result, Evotec said it will record a charge of up to €22 million ($30.2 million) and lowered its 2013 guidance. The company now expects 2013 revenues of €84-€86 million ($115.2-$117.9 million), down from its previous guidance of €90-€100 million...

Read the full 300 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >